In a field where precision, reliability, and trust define outcomes, SeqMatic has emerged as a standout in the next-generation sequencing (NGS) and omics services landscape.
Life Sciences Review Magazine has selected SeqMatic as the "NGS Omics Sequencing Services of the Year 2026." The recognition comes from a survey of the magazine’s readership of more than 200,000 professionals, which asked about their experiences with NGS omics sequencing providers. The key evaluation criteria included:
• Scientific knowledge and technical expertise
• Quality and consistency of the data delivered
• Sympathy and comprehension of customer challenges
• Communication and transparency during the project lifecycle
• Turnaround time
• Overall value for money
Many scientists noted their frustration when sending carefully prepared samples to a service provider, only to receive subpar results caused by misaligned priorities or insufficient expertise. Selecting the wrong provider can be both costly and time-consuming, with consequences that may derail the progress of a critical project or even affect the direction of an entire company.
It is precisely this gap that defines SeqMatic's operating philosophy.
While most sequencing service providers rely on a traditional sales model in which customers interact mainly with sales representatives, SeqMatic adopts a distinctly different approach. Its customers engage directly with the scientists processing their samples. Whether the project demands a tight deadline, rare specimens, or an unconventional non-model organism, SeqMatic customers know exactly who is accountable for their project.
At the core of this approach is a culture that prioritizes accountability, accessibility, and scientific precision. “What truly differentiates SeqMatic is our culture. Our team is resourceful, resilient, and deeply committed to customer success,” said Len Goren, CEO. That commitment is evident in how the company structures its workflows, engages with customers, and handles even the most complex sequencing challenges.
“We realize that every sample represents significant effort—often weeks of preparation by our customers— and in many cases represents a patient, an animal study, or irreplaceable biological material. Because of this, we treat every sample with the care and respect it deserves,” says Goren.
Reducing Scientific Risk
What factors influence trust, precision, and reliability in omics sequencing service providers?
SeqMatic never reduces costs by sacrificing quality. It uses validated commercial kits and performs quality checks throughout workflows to ensure reliable, reproducible results. This includes checkpoints where they pause and troubleshoot if results fall outside expectations.
One example is its standard MiSeq spike-in validation step performed before loading libraries onto high-throughput sequencers. This validation run confirms key parameters, including read length distribution, GC content, species confirmation, library balance, and adapter contamination or preparation errors. This prevents wasted sequencing runs and assures that customers receive meaningful data. This additional QC step lets SeqMatic optimize flow cell loading, often delivering 10–20% more data than vendor specifications, improving both data quality and cost efficiency.
Many US biotech companies have experienced data security breaches and concerns with data protection. SeqMatic further mitigates risk through full compliance with the BIOSECURE Act and robust HIPAA and SOC 2 Type 2 protection of customer data.
Turning Challenging Samples into Usable Data
How does direct scientist engagement improve accountability and communication in sequencing workflows?
Another core distinction identified in the survey was SeqMatic’s expertise with challenging samples.
The survey indicated that many service providers depend heavily on automation. While automation accelerates routine processes, it struggles with difficult, low-input, or degraded samples. Even the most advanced laboratory robots maintain high sample input requirements. SeqMatic takes a different stance: they customize protocols, purify samples and use specialized chemistries to recover trace amounts of DNA or RNA. They still use robotics where it’s valuable, but they prioritize pristine data quality and flexibility over automation.
Case study: A customer submitted human plasma samples containing miniscule quantities of viral RNA. Goal of the study was to identify the virus. SeqMatic’s dedicated RNA team performed a manual extraction on the samples and recovered a small amount of RNA – less than 1 nanogram per sample.
SeqMatic selected a specialized low-input RNA kit and modified its protocol to amplify the low RNA signal. SeqMatic scientists recovered and reconstructed the entire viral genome—an outcome that seemed unlikely given the RNA extraction results.
Another example is how SeqMatic discovers biomarkers in low-tumor-content solid tissue samples from FFPE blocks or slides. In these cases, SeqMatic applies a novel technology that integrates a 3rd party proprietary chemistry with AI-based pathology analysis to identify, isolate and enrich tumor DNA from heterogeneous tissue samples. This approach produces highly purified tumor DNA or RNA suitable for sequencing even when the total yield is very low.
-
"We’ve worked with multiple NGS providers, and SeqMatic stands out. They are very responsive, with great customer service, and being local has been very helpful, especially on tight timelines. They understand startups, are empathetic, reasonable, and transparent. As a deep expert in NGS and multiomics, I am particular about vendors. Their team is always available for a quick reality check and helps move projects forward with a real can-do attitude. They give good advice, offer competitive quotes, and are willing to go the extra mile. All of this makes them feel like a trusted extended part of our team. We really enjoy working with them. Thanks, team, and keep up the good work.” – Dr. Eswar Iyer, CEO of Aikium Inc.
Another example is how SeqMatic discovers biomarkers in low-tumor-content solid tissue samples from FFPE blocks or slides. In these cases, SeqMatic applies a novel technology that integrates a 3rd party proprietary chemistry with AI-based pathology analysis to identify, isolate and enrich tumor DNA from heterogeneous tissue samples. This approach produces highly purified tumor DNA or RNA suitable for sequencing even when the total yield is very low.
Respondents also noted “Onsite-seq”, SeqMatic’s mobile single-cell fixation service. It’s well known that cryopreservation reduces cell viability. With Onsite-seq, SeqMatic scientists travel directly to the customer’s lab with the necessary equipment to stabilize and fix cells immediately after isolation. The stabilized samples are then transported back to the SeqMatic laboratory to complete the workflow. This novel service dramatically improves cell viability and overall data quality and can be the determining factor for a successful experiment.
Bringing NGS into the Clinic
Why are quality control checkpoints essential for ensuring reliable and reproducible sequencing results?
Looking ahead, in additional to expending their omics portfolio for research applications, SeqMatic expects continued growth in clinical sequencing assays. Physicians are adopting genetics to guide diagnosis and treatment decisions. SeqMatic is leveraging its CLIA / CAP certifications to bring sequencing into the clinic. It is one of a few sequencing service providers that support both research and clinical sequencing projects within a CLIA/CAP-accredited laboratory environment.
SeqMatic partners with biotech companies to validate omics assays as laboratory-developed tests or 510(k) approved diagnostics. Sometimes they execute the full workflow, from sample extraction to reporting. Other times they deliver raw sequencing data to their partners, who specialize in converting raw data into valuable biological insights. These partnerships are enabling scientists to leverage genomics to solve the biggest challenges in biology, such as early detection of Alzheimer’s disease, microbiome optimization, and development of age-reversal therapeutics.
Operational Excellence in Omics
In what way do customized protocols improve outcomes for low-input or degraded samples?
SeqMatic integrates scientific rigor, technological sophistication, and personalized service in the NGS and omics services space. Its dedication to quality, regulatory compliance, and operational excellence ensures reliable outcomes across a diverse range of sequencing applications. By blending innovation with empathy and technical expertise with strategic partnerships, SeqMatic continues to enable discoveries that advance both research and clinical practice, securing its position as a leading provider in the global genomics landscape.
“We sincerely appreciate and thank Life Sciences Review Magazine for the recognition, but the real credit belongs to our customers, who have trusted us with their research over the past 14 years. Their challenges push us to innovate, improve, and continually raise the standard for sequencing services. It has been an honor to support their discoveries, and we look forward to continuing those partnerships in the years ahead,” says Len Goren, CEO of SeqMatic.
Evaluating Precision, Reliability in Omics Sequencing Services
Advances in next-generation sequencing have expanded the scope of biological discovery, yet they have also increased pressure on research teams to select service providers that can deliver dependable data under varied and often unpredictable conditions. For executives responsible for sourcing omics sequencing services, the challenge is less about access to technology and more about ensuring that the output is scientifically meaningful, reproducible and aligned with specific research objectives. Laboratories today face constraints ranging from limited sample quality to compressed timelines, making service quality inseparable from project success.
A consistent concern across life sciences organizations is the variability in data quality when workflows are treated as standardized pipelines rather than adaptive scientific processes. Sequencing outcomes depend heavily on upstream preparation, quality control discipline and the ability to identify and correct issues before they propagate into downstream analysis. Providers that rely solely on automated workflows often struggle when confronted with low-input or degraded samples, creating a risk of failed runs or incomplete datasets. Strong service partners address this gap by embedding checkpoints across the workflow, allowing for intervention, correction and optimization before expensive sequencing steps begin.
Equally important is the relationship between scientific teams and the service provider. Many sequencing engagements still operate through indirect communication models, where clients interact primarily with account representatives while the technical execution remains opaque. This structure limits the ability to refine project design in real time or respond to unexpected challenges. Direct engagement with scientific teams introduces clarity, enabling alignment on experimental goals, methodological trade-offs and expected outcomes. It also creates accountability, ensuring that decisions made during the sequencing process are grounded in the project’s scientific intent rather than procedural convenience.
Another defining factor is how providers approach complex or non-standard use cases. Research increasingly extends beyond well-characterized human or model organism systems, requiring adaptation of protocols and thoughtful selection of sequencing platforms. Flexibility in matching technologies to specific biological questions improves both sensitivity and interpretability of results. Long-read sequencing, high-throughput short-read platforms and emerging multiomic approaches each serve distinct purposes, and their value depends on careful alignment with experimental design. Providers that can navigate these choices while maintaining cost efficiency offer a clear advantage to organizations balancing innovation with budget discipline.
Turnaround time remains a practical constraint, yet speed without quality introduces risk rather than value. Efficient providers achieve faster timelines not by bypassing validation steps but by optimizing coordination, resource allocation and workflow design. The ability to recover usable data from difficult samples, reduce reruns and deliver consistent outputs ultimately compresses project timelines more effectively than superficial acceleration.
Within this landscape, SeqMatic presents a model grounded in scientific accountability and adaptive execution. It emphasizes direct interaction between clients and the scientists responsible for each project, allowing research objectives to guide workflow decisions from the outset. Its approach to quality control includes validation steps before high-throughput sequencing, enabling correction of library issues and optimization of sequencing conditions, which often results in higher data yield and improved cost efficiency.
It also demonstrates strength in handling challenging samples, applying modified protocols and specialized chemistries to recover data where conventional pipelines fail. Its ability to align sequencing platforms with specific research needs, combined with support for both research and clinical workflows within a compliant laboratory environment, positions it as a dependable partner for organizations navigating increasingly complex omics projects.
...Read more
